Point Of Care Molecular Diagnostics Market Expected To Trigger A Revenue Increase To USD USD 3.9 Billion By 2024:Key Participant Cepheid, Bio-Rad Laboratories, bioMerieux

San Francisco, 29 November 2018,  Global pointof care molecular diagnostics market is anticipated to reach USD 3.9 billion by 2024, according to a new report by Grand View Research, Inc. Ongoing research & development to miniaturize molecular diagnostics testing that provides enhanced near patient testing with high accuracy & lesser turnaround times are major factors expected to reinforce the high growth potential for POC MDx products.

Growing demand for CLIA tests that are, by definition, portable and safe enough to be used in non-laboratory settings such as pharmacy clinics, physician offices, and home-care settings, is expected to drive demand in the market over the forecast period. Ongoing research and development is continually supported and funded by a number of major international entities including the national governments of developed countries and high-value private funding agencies such as the Bill & Melinda Gates Foundation.

Furthermore, a growing portfolio of point-of-care testing capabilities that, had initially been focused on screening, testing, and diagnosis of infectious diseases in low-income developing countries, has been developing at a rapid pace over the past decade to expand its potential market to a broader range of medical faculties. Consequently, POC and molecular diagnosis tests are available and/or are under development for cardiology monitoring, oncology testing, and hematology testing.

Recent advances in the development of microfluidics and genetic sequencing instrumentation pave the way for development of cost-effective, highly accurate and rapid testing platforms, which are able to be used as true POC systems. This is a key factor that significantly contributes towards the favorably funded, high growth potential environment prevalent in the point of care molecular diagnostics market.

Access Full Research Report On Point Of Care Molecular Diagnostics Market Analysis:
www.grandviewresearch.com/industry-analysis/point-of-care-poc-molecular-diagnostics-market

Further key findings from the report suggest:

·         Application of POC MDx tests for infectious diseases accounted for over 45% of market revenue in 2015. The large share can be accounted for by the presence of an extensive portfolio of the concerned tests with a number of major market entities. Furthermore, growing disease burden of infectious diseases in developing as well as developed countries is another factor the reinforces the dominance of this segment.

·         PCR-based POC tests accounted for the largest share of the market in 2015. Widespread usage of PCR-based techniques for molecular diagnosis and commercialization of POC real time PCR products such as the cobas LIAT by Roche have provided this segment with ample opportunities for revenue generation and are expected to maintain a favorable market environment over the forecast period.

·         North America was observed to be the most lucrative region on this market and estimated to account for over 40% of the global revenue. presence of a technologically advanced medical framework, sophisticated insurance & copayment system & high R&D investment by governments and private funding organizations for the development of POC MDx tests are major factors responsible for the region’s dominant market position.

·         Key players operating in this industry include Johnson & Johnson, Danaher Corp., Cepheid, Bio-Rad Laboratories, bioMerieux, Becton Dickinson, Roche Diagnostics, Bayer Healthcare, Alere Inc (Abbott), Abbott Laboratories among others.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented point of care molecular diagnostics market on the basis of workflow, mode, services, and region:

Global Point of Care Molecular Diagnostics Application Outlook (Revenue, USD Million, 2013 - 2024)

·         Infectious Diseases

·         Oncology

·         Hematology

·         Prenatal Testing

·         Endocrinology

·         Other Applications

Global Point of Care Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2013 - 2024)

·         PCR-based

·         Genetic Sequencing-based

·         Hybridization-based

·         Microarray-based

Global Point of Care Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2013 - 2024)

·         OTC

·         POC

Global Point of Care Molecular Diagnostics End-use Outlook (Revenue, USD Million, 2013 - 2024)

·         Decentralized Labs

·         Hospitals

·         Home-care

·         Assisted Living Healthcare Facilities

·         Other uses

Point of Care Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Brazil

·         MEA

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-point-of-care-poc-molecular-diagnostics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Therapeutic Drug Monitoring Market Expected To Trigger A Revenue Increase To USD 3.37 Billion By 2024:Key Participant Siemens Healthcare GmbH

San Francisco, 24 October 2018 , The global therapeutic drug monitoring market is expected to reach over USD 3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. However, the broad application of the PoC devices for patient monitoring is still lagging behind. The presence of this untapped opportunity is one of the high impact rendering drivers for the market growth.

The employment of continuous therapeutic drug and metabolite monitoring in the early phase of the medication regimen, administered post-organ transplantation, forms a major application in the areas of critical care medicine and organ transplantation, which is expected to propel the growth of the therapeutic drug monitoring market over the forecast period. In addition, the imposing burden of diseases, such as epilepsy and cancer, the rising government initiatives, and the presence of high-unmet needs are some of the crucial determinants expected to further favor the emergence of this market.

Full Research Report On Therapeutic Drug Monitoring Market Analysis:
www.grandviewresearch.com/industry-analysis/therapeutic-drug-monitoring-market

Further key findings from the study suggest:

·         The consumables segment covered over 65% of the market share in 2015 as a consequence of the extensive requirement of the consumables in the research laboratories and due to the repeat purchase of the kits and reagents.

·         The immunoassay segment held the largest market share in 2015. The presence of several commercially available immunoassays combined with their associated benefits including the cost effectiveness and easy-to-handle nature of the products are the key drivers for the growth of this segment.

·         The proteomics category is expected to be the fastest growing technology segment due to the advent of various proteomic technologies, such as isotope-coded affinity tags, next generation sequencing, and protein microarray platforms that enable rapid mining of the proteome.

·         The hospital is the largest end-use segment with a share of over 60% in 2015. In larger hospitals, various underlying technologies are employed to perform immunoassays; these comprise chemiluminescence, nephelometry, colorimetry, and fluorescence, which are available for the testing of a wide ranging drug panel.

·         The drug monitoring for the immunosuppressants is one of the fastest growing application segments owing to the introduction of novel TDM point-of-care testing devices for the evaluation of the concentration of administered immunosuppressants and the complementary metabolites, in order to achieve a prominent therapeutic effect while preventing drug toxicity events in patients that have undergone transplantations.

·         In 2015, North America was the highest revenue generating region with revenue generated over USD 900 million. The rising number of R&D activities coupled with the high awareness about personalized therapy is the major determining factor for the large share captured by the North America region.

·         Few of the leading market players are Roche Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMérieux, Inc., and Alere, Inc. The persistent R&D efforts are being undertaken along with numerous other strategic endeavors being adopted by the market players with the objective of enhancing the present drug monitoring practices and to develop novel technologies.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the therapeutic drug monitoring market on the basis of product, technology, application, end-use, and region:

Therapeutic Drug Monitoring Market, Product Outlook, by Revenue (USD Million, 2013 - 2024)

·         Consumables

·         Equipment

·         Others

Therapeutic Drug Monitoring Market, Technology Outlook, by Revenue (USD Million, 2013 - 2024)

·         Immunoassays

·         Proteomic technologies

·         Others

Therapeutic Drug Monitoring Market Drug, Class Outlook, by Revenue (USD Million, 2013 - 2024)

·         Anti-epileptics

·         Antibiotics

·         Immunosuppressants

·         Psychoactive drugs

·         Antiarrhythmic drugs

·         Others

Therapeutic Drug Monitoring Market, End-use Outlook, by Revenue (USD Million, 2013 - 2024)

·         Hospital labs

·         Private labs

·         Others

Therapeutic Drug Monitoring Market, Regional Outlook, by Revenue (USD Million, 2013 - 2024)

·         North America

o    U.S.

o    Canada

·         Europe

o    UK

o    Germany

·         Asia Pacific

o    Japan

o    China

·         Latin America

o    Brazil

·         MEA

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-medical-alert-personal-emergency-response-system-pers-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Cardiac Biomarkers Market Expected To Trigger A Revenue Increase To USD 13.3 Billion By 2024:Key Participant Alere, Inc., Siemens Healthcare GmbH

San Francisco, 10 October 2018, The Cardiac Biomarkers Market is expected to reach USD13.3 billion by 2024, according to a new report by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth during the forecast period from 2016 to 2024.
Analysis of global market trends focuses on the increasing demand for cardiac biomarkers owing to its increased adoption in cardiovascular disease diagnosis. Furthermore, this growth is attributed to a majority of factors, such as the high prevalence of Acute Coronary Syndrome (ACS), continual technological advancements in the development of cardiovascular biomarkers, increasing number of new product launches by the key market players, rising demand for point of care cardiac testing kits, along with the high specificity and sensitivity of these biomarkers in the detection of cardiovascular diseases, especially acute myocardial infarction.
The cardiac biomarkers market has been classified by type into troponin, Creatine kinase-MB(CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, and others. Troponin is a heteromeric protein and comprises cardiac troponin T & I, which are abbreviated as cTnT & cTnI, respectively. The troponin biomarkers segment is expected to grow lucratively in the forecast period at a significant CAGR. The diagnostic efficiency and specificity related to cardiac biomarker testing renders it a universally gold standard test to diagnose cardiovascular disorders worldwide. The market by application is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, and others. ACS is expected to be the highest grossing segment according to the study. ACS is responsible for huge medical costs globally and is responsible for most hospital readmission cases. The increasing efforts to cut down worldwide ACS prevalence rates are expected to drive the growth of the biomarkers market.
The key countries included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and the Middle East. North America accounted for the largest market in 2015, whereas the Asia Pacific region is anticipated to be the fastest growing region during the forecast period.
Full Research Report On cardiac biomarkers market Analysis:www.grandviewresearch.com/industry-analysis/cardiac-biomarker-market

 Further key findings from the study suggest:

• North America is estimated to dominate the global cardiac biomarkers market. The high prevalence of coronary heart disease in western countries is one of the major factors contributing to the high demand for cardiac biomarker diagnostics.
• The Asia Pacific region is anticipated to be the fastest growing region in the study period owing to the large population, especially in China and India. Apart from that, there exists a high prevalence rate of myocardial infarction in the region. This prevalence rate is expected to fuel the demand for cardiac biomarker diagnostics.
• The troponin biomarker segment is expected to grow at a significant rate, and is expected to grow at the highest CAGR compared to others and accounts for the largest market share in 2015.
• The sector comprises of several local as well as global players. Some of the major players of this vertical include Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, and bioMerieux SA.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the cardiac biomarkers market on the basis of type, application, end use, and region:
Cardiac Biomarkers Type Outlook (Revenue, USD Million, 2013 - 2024)

• Troponin
• CK-MB
• Natriuretic peptides - BNP and NT-proBNP
• Myoglobin
• Others

Cardiac Biomarkers Market Application Outlook (Revenue, USD Million, 2013 - 2024)

• Acute Coronary Syndrome
• Myocardial infarction
• Congestive heart failure
• Others

Cardiac Biomarkers Market End-use Outlook (Revenue, USD Million, 2013 - 2024)

• Laboratory Testing
• Point of Care Testing

Cardiac Biomarkers Regional Outlook (Revenue, USD Million, 2013 - 2024)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
• Asia Pacific
  • China
  • India
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Middle East

  Access Full Press Release of this Report: https://www.grandviewresearch.com/press-release/global-cardiac-biomarker-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/

Coagulation Analyzers Market To Surpass 7.9 Billion By 2024 | Key Industry Players Roche Diagnostics

Coagulation Analyzer market by region, 2015 & 2024

The global Coagulation Analyzers/Reagents Market is expected to reach USD 7.9 billion by 2024, according to a new report by Grand View Research, Inc. Rising technological advancements in coagulation analyzers are expected to be the most impact rendering driver for lucrative growth of the market. Automation is the key development that has occurred in recent years.

The most relevant advancement includes combination of different assay procedures in single equipment and various commercially available hemostasis analyzers, which are capable of performing tests such as Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), D-Dimer, and Fibrinogen as well as these machines can perform chromogenic and immunologic assays.

Moreover, these systems may have the capacity of holding more samples, providing faster results, and increasing the efficiency of laboratory workflow. The advancements in hemostasis analyzers are as follows:

·         Integration of the system with track line systems and work cells, which may improve the reliability of analysis in terms of single detection system and preanalytical check for interfering substances

·         Failure pattern sensors, which detect insufficient sample levels and clots and cap piercing, which enhances safety and sample integrity

·         Automatic reflex testing, repeat testing, and redilution

Full Research Report On Coagulation Analyzers/Reagents Market Analysis:

www.grandviewresearch.com/industry-analysis/coagulation-analyzers-market

Further key findings from the study suggest:

·         Clinical laboratory analyzers held over 70.0% of the market share in 2015 and are predicted to sustain its dominance over the forecast period.

·         Advantages such as use of whole blood as sample, no pre-analytical delay and requirement of lesser reagents, further boost growth of Point of Care analyzers.

·         Reagents held the highest market share in 2015. This dominance may be attributed to increasing usage of hemostasis analyzers coupled with easy availability of reagents.

·         Optical technology based hemostasis analyzers held the largest share in 2015 and is expected to grow at a CAGR of over 6.0% over the forecast period.

·         The market is majorly dominated by the prothrombin test. The APTT test is estimated to account for the second largest share in the market in 2015.

·         Hospitals are expected to witness lucrative growth over the forecast period. This can be attributed to high number of hospitals in developing economies.

·         For instance, Mexico has over 4,500 hospitals and out of these 67.0% hospitals are private and remaining 33.0% hospitals are public hospitals.

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the global Coagulation Analyzers & Reagents market on the basis of product, technology, test type, end-use and region.

Product Outlook (Revenue, USD Million, 2013 - 2024)

·         Analyzers

o    Clinical Laboratory Analyzers

o    Point of Care Analyzers   

·         Consumables

o    Reagents

o    Stains

Technology Outlook (Revenue, USD Million, 2013 - 2024)

·         Mechanical

·         Electrochemical

·         Optical

o    Photo optical/Chromogenic/Immuno

o    Others/Nephelometric

·         Others

Test Type Outlook (Revenue, USD Million, 2013 - 2024)

·         APTT

·         D-Dimer

·         Fibrinogen

·         Prothrombin

·         Others

End-Use Outlook (Revenue, USD Million, 2013 - 2024)

·         Hospitals

·         Research Institutes

·         Diagnostic Centers

·         Others

Regional Outlook (Revenue, USD Million, 2013 - 2024)

·         North America

o    U.S.

o    Canada

·         Europe

o    UK

o    Germany

·         Asia Pacific

o    Japan

o    China

·         Latin America

o    Brazil

o    Mexico

·         MEA

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-coagulation-analyzers-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com